Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

First RCT with aromatase inhibitor for male hypogonadism shows promise

Key clinical point: An experimental aromatase inhibitor was effective for treating men with hypogonadism while improving semen quality.

Major finding: On the highest tested dose, 90% of patients normalized their testosterone levels and serum concentrations were improved.

Data source: Double-blind randomized multicenter phase 2 trial.

Disclosures: Dr. Jones reported a financial relationship with Mereo BioPharma, the sponsor of this trial.

Citation:

Jones et al. ENDO 2019, Session OR18-4.